t131
Small moleculeexperimental
The M65 atomic cannon, often called Atomic Annie, was an artillery piece built by the United States and capable of firing a nuclear device. It was developed in the early 1950s, at the beginning of the Cold War; and fielded between April 1955 and December 1962, in West Germany, South Korea and on Okinawa. — Wikipedia
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2003 (NCT00952445)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
PPARG modulator
Selective PPAR gamma modulator (SPPAR?M)
Chemistry & pharmacology
Loading structure…
SMILES
O=S(=O)(Nc1cc(Cl)c(Oc2cnc3ccccc3c2)c(Cl)c1)c1ccc(Cl)cc1Cl- Mol. weight
- 514.22 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaM65 atomic cannon ↗
- ChEMBLCHEMBL1236924 ↗
Also known as
- amg131
- amg 131
- amg-131
- amg-131
- amg-131
- int131
- int131
- int131
- int131
- int 131
- int-131
- int-131
- int-131
- int-131
- t0903131
- t0903131
- t0903131
- t 0903131
- t-0903131
- t-0903131
- t-0903131
- t131
- t131
- t131
- t 131 cpd
- t-131 cpd
- t131 cpd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02638038 | Phase 2 | Feb 1, 2015 | Coherus BioSciences, InteKrin Therapeutics, Inc. |
| NCT00631007 | Phase 2 | Feb 1, 2008 | InteKrin Therapeutics, Inc., Medpace, Inc. |
| NCT00952445 | Phase 2 | Dec 1, 2003 | InteKrin Therapeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| InteKrin Therapeutics, Inc. | For profit | 3 | 3 | 1 | 2003 |
| Coherus BioSciences | For profit | 1 | 0 | 1 | 2015 |
| Medpace, Inc. | For profit | 1 | 0 | 1 | 2008 |
3 organizations
Page 1 / 1